Warburg Pincus Acquires 5.4% of WuXi PharmaTech's Outstanding Ordinary Shares from United Ove...(ved. Theseforward-looking statements are...)

Date:7/14/2008

ved. These forward-looking statements are not historical facts but instead represent only our belief regarding future events, which by their nature are inherently uncertain and outside of our control and actual results could differ materially. Our business is subject to numerous risks and this release should be read in conjunction with the consolidated and pro forma financial statements and notes thereto and related "Risk Factors", each included in our Annual Report on Form 20-F filed with the Securities and Exchange Commission and available on the Securities and Exchange Commission's website at http://www.sec.gov. We do not undertake any obligation to update or revise the forward-looking statements contained in this press release, whether as a result of new information, future events or otherwise, after the date of this press release. Such information speaks only as of the date of this release.

For more information, please contact:

Sherry Shao

Tel: +86-21-5046-4002

Email: pr@pharmatechs.com

'/>"/>

SOURCE WuXi PharmaTech (Cayman) Inc. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3
Related biology technology :

1. Bioniche Pharma Acquires Baxters ENLON(R) and ENLON-PLUS(R)
2. Neogen Acquires Product Line From DuPont Animal Health Solutions
3. Decision Resources, Inc. Acquires Manhattan Research
4. Fontus Pharmaceuticals Acquires Nephrology and Endocrinology Drug from Roche Laboratories Inc.
5. Miltenyi Biotec GmbH Acquires Medic Tools AG
6. Pacific Biosciences Acquires Single Molecule Sequencing Technology from LI-COR Biosciences
7. Touch Bionics acquires LIVINGSKIN
8. Beckman Coulter Acquires Rights to Hepatitis C Virus
9. China Yingxia International, Inc. Acquires Grocery Chain and Online Distribution Network
10. China Sky One Medical, Inc. Acquires Heilongjiang Haina Pharmaceutical Inc.
11. Royalty Pharma Acquires Royalty Interest in RotaTeq(R) from The Childrens Hospital Foundation for $182 Million